Sandu Pharmaceuticals Limited
BSE: SANDUPHQ.BO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Bombay Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Umesh Bhaskar Sandu
- Employees
- 283
- Headquarters
- Mumbai, India
- IPO year
- 2002
- Market cap
- ₹379.9M
- Website
- http://www.sandu.in
Loading SANDUPHQ…
Loading profile data…Frequently asked questions about SANDUPHQ
What does Sandu Pharmaceuticals Limited (SANDUPHQ.BO) do?
Sandu Pharmaceuticals Ltd. engages in the manufacture and marketing of Ayurvedic medicines. It offers its products under the Berbenteron suspension, Berbenteron tablets, Bilagyl, Debix, Elegance Oil, Ephenin, Haemol Forte, Madiphal Rasayan, Osteon D, Pregutero, Sarak, Shatari, Stresan, Jaundex, Vanari Kalpa, Vimfix, Whoopin and Pentazyme brands....
Where does SANDUPHQ.BO trade?
Sandu Pharmaceuticals Limited (SANDUPHQ.BO) trades on the Bombay Stock Exchange.
What sector is SANDUPHQ.BO in?
Sandu Pharmaceuticals Limited (SANDUPHQ.BO) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Sandu Pharmaceuticals Limited?
Umesh Bhaskar Sandu is the chief executive officer of Sandu Pharmaceuticals Limited (SANDUPHQ.BO).
Where is Sandu Pharmaceuticals Limited headquartered?
Sandu Pharmaceuticals Limited is headquartered in India.
Does SANDUPHQ.BO pay a dividend?
Yes — Sandu Pharmaceuticals Limited (SANDUPHQ.BO) paid a trailing twelve-month dividend of INR 0.80 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did SANDUPHQ.BO go public?
Sandu Pharmaceuticals Limited (SANDUPHQ.BO) completed its initial public offering in 2002.